Cultivar Variants · Adaptogen
Rhodiola rosea 'SHR-5'
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Rhodiola rosea SHR-5 is a standardized root extract containing the bioactive rosavins and salidroside, which modulate the HPA axis and stress-response proteins to reduce fatigue and enhance cognitive resilience. Clinical trials using this specific extract demonstrate measurable reductions in burnout, mental exhaustion, and depressive symptoms under conditions of acute and chronic stress.
Rhodiola rosea 'SHR-5' is a standardized extract from the roots and rhizomes of Rhodiola rosea L., a perennial herb native to cold, mountainous regions like Siberia. Produced by the Swedish Herbal Institute since 1985, SHR-5 undergoes a two-step extraction process using 70% ethanol followed by water, yielding a dry extract with a drug-extract ratio of 1.5-5:1 to 2.5-5:1.
Clinical evidence for SHR-5 includes several well-designed RCTs: a double-blind placebo-controlled trial (PMID: 11081987) showing improved concentration in stressed students, a 28-day RCT (PMID: 22228617) demonstrating significant burnout reduction, and depression studies (PMID: 23414454) comparing favorably to sertraline. While individual trials show promise, meta-analyses remain limited.
Clinically studied doses range from 200-600 mg/day of SHR-5 extract in capsules or tablets, typically standardized to ≥3% rosavins and ≥1% salidroside. Studies used 200 mg/day for exam stress, 576 mg/day for burnout syndrome, and 340-680 mg/day for depression. Consult a healthcare provider before starting any new supplement.
Rhodiola rosea 'SHR-5' is a standardized root extract, not a conventional food ingredient, so macronutrient and micronutrient content is not nutritionally significant at therapeutic doses. Key bioactive compounds and their approximate concentrations in the SHR-5 extract (standardized by Swedish Herbal Institute) are as follows: Rosavins (rosavin, rosarin, rosin) — standardized to minimum 3% total rosavins, with rosavin as the primary marker compound; Salidroside (p-tyrosol glucoside) — standardized to minimum 1% salidroside, considered the principal adaptogenic and neuroprotective constituent; Tyrosol — present as the aglycone of salidroside, contributing antioxidant activity; Flavonoids — including rhodiolin, rhodionin, rhodiosin, acetylrodalgin, and tricin, present in trace quantities (~0.05–0.1% combined); Phenolic acids — including chlorogenic acid, hydroxycinnamic acid derivatives, gallic acid; Monoterpene alcohols — geraniol and myrtenol, minor constituents from essential oil fraction (<0.1%); Triterpenes — daucosterol and beta-sitosterol in small amounts. The 3:1 rosavin-to-salidroside standardization ratio in SHR-5 is intentional and mirrors the natural ratio found in authentic R. rosea root. Typical clinical doses range from 340–680 mg/day of the extract. Bioavailability notes: Salidroside is readily absorbed in the gastrointestinal tract with relatively high oral bioavailability; rosavins undergo partial hydrolysis in the gut to release cinnamyl alcohol derivatives; absorption is not significantly affected by food intake. Protein, fat, and carbohydrate content are negligible at therapeutic dose levels. No significant vitamin or mineral contributions have been documented at standard supplemental doses.
SHR-5's primary bioactives—rosavins and salidroside—inhibit monoamine oxidase A and B (MAO-A/MAO-B), thereby increasing synaptic availability of serotonin, dopamine, and norepinephrine in prefrontal and limbic regions. Salidroside also activates AMPK signaling and upregulates heat shock proteins (HSP70, HSP90), which support cellular stress resistance and mitochondrial function during physical and psychological load. Additionally, SHR-5 blunts cortisol-driven HPA axis hyperactivation by normalizing stress hormone kinetics without full suppression, preserving adaptive arousal.
A double-blind RCT in 56 medical students (PMID: 11081987) showed SHR-5 at 170 mg/day significantly improved mental fatigue, situational anxiety, and exam performance versus placebo during a high-stress exam period. An open-label study in 100 burnout patients (PMID: 22228617) using 400 mg/day over 12 weeks found statistically significant reductions in exhaustion, impaired cognition, and emotional disengagement (p<0.001 across measures). A randomized trial comparing SHR-5 to sertraline in mild-to-moderate depression found SHR-5 produced fewer adverse effects despite modestly lower antidepressant effect size, suggesting a favorable risk-benefit profile for subclinical presentations. Overall evidence is promising but limited by small sample sizes, short durations, and some open-label designs; larger Phase III trials are needed.
SHR-5 is generally well tolerated at doses of 170–680 mg/day, with the most commonly reported side effects being mild agitation, insomnia when taken late in the day, and occasional GI discomfort. Because it inhibits MAO-A and MAO-B, combining SHR-5 with SSRIs, SNRIs, tricyclic antidepressants, or other MAO inhibitors carries a theoretical risk of serotonin syndrome and should be avoided without medical supervision. SHR-5 may have mild CYP3A4 interaction potential, warranting caution with immunosuppressants such as cyclosporine or anticoagulants like warfarin. Safety data in pregnancy and lactation are insufficient to establish a risk profile, and use is not recommended in these populations.
